IQVIA HLDGS INC's ticker is IQV and the CUSIP is 46266C105. A total of 995 filers reported holding IQVIA HLDGS INC in Q2 2024. The put-call ratio across all filers is 5.08 and the average weighting 0.3%.
About IQVIA HLDGS INC
IQVIA Holdings Inc. is a leading provider of advanced analytics, technology solutions, and contract research services to the life sciences industry. The company operates in more than 100 countries and has a workforce of over 70,000 employees. IQVIA's mission is to help its clients improve their clinical, scientific, and commercial results.
IQVIA's services include clinical trial design and management, real-world evidence solutions, commercialization services, and technology solutions. The company's technology solutions include advanced analytics, artificial intelligence, and machine learning capabilities that help its clients make better decisions and improve their outcomes.
IQVIA has a strong track record of growth and profitability. In 2020, the company reported revenue of $11.1 billion, an increase of 5.5% compared to the previous year. The company's net income for the year was $1.1 billion, an increase of 16.7% compared to the previous year.
IQVIA's success is driven by its focus on innovation and its ability to adapt to the changing needs of the life sciences industry. The company has made significant investments in technology and data analytics capabilities, which have helped it to stay ahead of the competition.
In conclusion, IQVIA Holdings Inc. is a leading provider of advanced analytics, technology solutions, and contract research services to the life sciences industry. The company's focus on innovation and its ability to adapt to the changing needs of the industry have helped it to achieve strong growth and profitability. With a strong track record of success, IQVIA is well-positioned to continue to deliver value to its clients and shareholders in the years ahead.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $26,417,962 | -23.6% | 132,827 | -21.3% | 0.44% | -36.1% |
| Q4 2022 | $34,597,930 | +13.4% | 168,861 | +0.3% | 0.68% | +6.4% |
| Q3 2022 | $30,503,000 | -28.9% | 168,396 | -14.9% | 0.64% | -50.3% |
| Q2 2022 | $42,931,000 | -0.4% | 197,850 | +6.2% | 1.29% | +26.6% |
| Q1 2022 | $43,092,000 | -18.6% | 186,374 | -0.7% | 1.02% | +4.5% |
| Q4 2021 | $52,960,000 | +16.8% | 187,709 | -0.8% | 0.97% | +30.2% |
| Q3 2021 | $45,342,000 | -12.8% | 189,289 | -11.8% | 0.75% | -10.6% |
| Q2 2021 | $52,007,000 | +36.0% | 214,620 | +8.4% | 0.84% | +21.0% |
| Q1 2021 | $38,248,000 | +7.0% | 198,030 | -0.7% | 0.69% | +22.9% |
| Q4 2020 | $35,730,000 | +13.3% | 199,420 | -0.3% | 0.56% | +10.0% |
| Q3 2020 | $31,545,000 | -9.0% | 200,120 | -18.1% | 0.51% | -24.9% |
| Q2 2020 | $34,651,000 | +32.1% | 244,230 | +0.4% | 0.68% | +2.6% |
| Q1 2020 | $26,226,000 | -36.0% | 243,146 | -8.3% | 0.66% | -30.3% |
| Q4 2019 | $40,968,000 | +10.3% | 265,150 | +6.6% | 0.95% | -4.8% |
| Q3 2019 | $37,149,000 | – | 248,690 | – | 1.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RIT CAPITAL PARTNERS PLC | 239,000 | $57,912,000 | 19.53% |
| COWBIRD CAPITAL LP | 114,449 | $27,733,000 | 9.42% |
| Eagle Health Investments LP | 85,277 | $20,664,000 | 7.09% |
| KENSICO CAPITAL MANAGEMENT CORP | 889,900 | $215,641,000 | 6.23% |
| Brahman Capital Corp. | 322,638 | $78,182,000 | 5.77% |
| Longview Partners (Guernsey) LTD | 4,227,653 | $1,024,445,000 | 5.63% |
| KDI CAPITAL PARTNERS LLC | 68,606 | $16,625,000 | 5.48% |
| TRAN CAPITAL MANAGEMENT, L.P. | 246,665 | $59,772,000 | 4.93% |
| Vontobel Swiss Wealth Advisors AG | 33,995 | $8,037,000 | 4.13% |
| McGuire Investment Group, LLC | 89,454 | $21,677,000 | 4.11% |